Literature DB >> 23143229

APP mutations in the Aβ coding region are associated with abundant cerebral deposition of Aβ38.

Maria Luisa Moro1, Giorgio Giaccone, Raffaella Lombardi, Antonio Indaco, Andrea Uggetti, Michela Morbin, Stefania Saccucci, Giuseppe Di Fede, Marcella Catania, Dominic M Walsh, Andrea Demarchi, Annemieke Rozemuller, Nenad Bogdanovic, Orso Bugiani, Bernardino Ghetti, Fabrizio Tagliavini.   

Abstract

Aβ is the main component of amyloid deposits in Alzheimer disease (AD) and its aggregation into oligomers, protofibrils and fibrils is considered a seminal event in the pathogenesis of AD. Aβ with C-terminus at residue 42 is the most abundant species in parenchymal deposits, whereas Aβ with C-terminus at residue 40 predominates in the amyloid of the walls of large vessels. Aβ peptides with other C-termini have not yet been thoroughly investigated. We analysed Aβ38 in the brains of patients with Aβ deposition linked to sporadic and familial AD, hereditary cerebral haemorrhage with amyloidosis, or Down syndrome. Immunohistochemistry, confocal microscopy, immunoelectron microscopy, immunoprecipitation and the electrophoresis separation of low molecular weight aggregates revealed that Aβ38 accumulates consistently in the brains of patients carrying APP mutations in the Aβ coding region, but was not detected in the patients with APP mutations outside the Aβ domain, in the patients with presenilin mutations or in subjects with Down syndrome. In the patients with sporadic AD, Aβ38 was absent in the senile plaques, but it was detected only in the vessel walls of a small subset of patients with severe cerebral amyloid angiopathy. Our results suggest that APP mutations in the Aβ coding region favour Aβ38 accumulation in the brain and that the molecular mechanisms of Aβ deposition in these patients may be different from those active in patients with familial AD associated with other genetic defects and sporadic AD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23143229     DOI: 10.1007/s00401-012-1061-x

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  14 in total

1.  Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients.

Authors:  Joel C Watts; Carlo Condello; Jan Stöhr; Abby Oehler; Joanne Lee; Stephen J DeArmond; Lars Lannfelt; Martin Ingelsson; Kurt Giles; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

2.  Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice.

Authors:  Jan Stöhr; Carlo Condello; Joel C Watts; Lillian Bloch; Abby Oehler; Mimi Nick; Stephen J DeArmond; Kurt Giles; William F DeGrado; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

Review 3.  Clearance systems in the brain-implications for Alzheimer disease.

Authors:  Jenna M Tarasoff-Conway; Roxana O Carare; Ricardo S Osorio; Lidia Glodzik; Tracy Butler; Els Fieremans; Leon Axel; Henry Rusinek; Charles Nicholson; Berislav V Zlokovic; Blas Frangione; Kaj Blennow; Joël Ménard; Henrik Zetterberg; Thomas Wisniewski; Mony J de Leon
Journal:  Nat Rev Neurol       Date:  2015-07-21       Impact factor: 42.937

Review 4.  Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.

Authors:  S Hunter; C Brayne
Journal:  Mol Psychiatry       Date:  2017-11-07       Impact factor: 15.992

5.  Aβ43 aggregates exhibit enhanced prion-like seeding activity in mice.

Authors:  Alejandro Ruiz-Riquelme; Alison Mao; Marim M Barghash; Heather H C Lau; Erica Stuart; Gabor G Kovacs; K Peter R Nilsson; Paul E Fraser; Gerold Schmitt-Ulms; Joel C Watts
Journal:  Acta Neuropathol Commun       Date:  2021-05-10       Impact factor: 7.801

Review 6.  The existence of Aβ strains and their potential for driving phenotypic heterogeneity in Alzheimer's disease.

Authors:  Heather H C Lau; Martin Ingelsson; Joel C Watts
Journal:  Acta Neuropathol       Date:  2020-08-02       Impact factor: 17.088

7.  The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ.

Authors:  Hannu Kalimo; Maciej Lalowski; Nenad Bogdanovic; Ola Philipson; Thomas D Bird; David Nochlin; Gerard D Schellenberg; Rosemarie Brundin; Tommie Olofsson; Rabah Soliymani; Marc Baumann; Oliver Wirths; Thomas A Bayer; Lars N G Nilsson; Hans Basun; Lars Lannfelt; Martin Ingelsson
Journal:  Acta Neuropathol Commun       Date:  2013-09-10       Impact factor: 7.801

Review 8.  Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System.

Authors:  Jonathan Janssens; Harmonie Etienne; Sherif Idriss; Abdelkrim Azmi; Bronwen Martin; Stuart Maudsley
Journal:  Front Endocrinol (Lausanne)       Date:  2014-09-01       Impact factor: 5.555

9.  Abundance of Aβ₅-x like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease.

Authors:  Erika Avendaño Guzmán; Yvonne Bouter; Bernhard C Richard; Lars Lannfelt; Martin Ingelsson; Anders Paetau; Auli Verkkoniemi-Ahola; Oliver Wirths; Thomas A Bayer
Journal:  Mol Neurodegener       Date:  2014-04-02       Impact factor: 14.195

10.  The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects.

Authors:  Thomas H Langenickel; Chiaki Tsubouchi; Surya Ayalasomayajula; Parasar Pal; Marie-Anne Valentin; Markus Hinder; Stanford Jhee; Hakop Gevorkyan; Iris Rajman
Journal:  Br J Clin Pharmacol       Date:  2016-03-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.